A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 83,042 shares of ALXO stock, worth $148,645. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,042
Previous 27,014 207.4%
Holding current value
$148,645
Previous $162,000 6.79%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$1.81 - $8.13 $101,410 - $455,507
56,028 Added 207.4%
83,042 $151,000
Q2 2024

Aug 09, 2024

SELL
$5.84 - $17.56 $12,088 - $36,349
-2,070 Reduced 7.12%
27,014 $162,000
Q1 2024

May 09, 2024

BUY
$10.95 - $16.79 $172,736 - $264,862
15,775 Added 118.53%
29,084 $324,000
Q4 2023

Feb 09, 2024

BUY
$4.81 - $15.38 $64,016 - $204,692
13,309 New
13,309 $198,000

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $72.9M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.